市场调查报告书
商品编码
1617202
到 2030 年单侧双埠内视镜的市场预测:按产品、应用、最终用户和地区进行的全球分析Unilateral Biportal Endoscopy Market Forecasts to 2030 - Global Analysis By Product (Reusable and Single-use), Application (Decompression, Deherniation, Spinal Stabilization and Other Applications), End User and By Geography |
根据Stratistics MRC预测,2024年全球单侧双口内视镜市场规模将达到9.7716亿美元,预测期内复合年增长率为8.0%,预计到2030年将达到15.5062亿美元。
脊椎手术是一种复杂的微创手术技术(称为单侧双光束内视镜检查(UBE))的主要应用。高解析度相机和手术器械透过身体同一侧的两个小切口插入,以观察和治疗脊椎疾病。与开放性手术相比,UBE具有许多优点,包括组织损伤少、恢復快、肌肉脱离少。该技术对周围结构的干扰最小,并且能够精确地直接进入脊柱,为患者提供了比传统技术侵入性更小、更有效的选择,从而导致脊椎融合手术、椎间盘切除术和减压等手术变得越来越受欢迎。
美国国立卫生美国(NIH) 表示,与传统的开放式脊椎手术相比,微创脊椎手术(包括单侧和双侧内视镜检查等技术)可将恢復时间缩短高达50%,并减少手术后疼痛。
门诊治疗的需求不断增长
随着世界各地的医疗保健系统注重降低成本,门诊手术变得越来越普遍。此型号非常适合 UBE。因为其微创技术可以缩短住院时间和加快復原时间,使患者更快恢復正常活动。此外,越来越多的保险公司透过承保 UBE 手术来支持这一趋势,因为他们了解这种手术的效率和成本效益。随着医疗保健提供者寻求降低手术成本并减轻住院设施的负担,UBE 在门诊手术中的作用预计将会增强。
初始设备成本高
所需技术和设备的高成本是UBE广泛使用的主要障碍之一。 UBE 手术所需的内视镜工具、摄影机和先进影像系统的购买和维护成本很高。此外,这些系统需要医院和诊所的大量投资,这可能令人望而却步,尤其是在中低收入地区。儘管快速復健时间和缩短住院时间有可能节省长期成本,但高昂的初始成本可能会阻止一些医疗保健提供者实施 UBE。
技术开发与机器人技术的融合
UBE 和机器人辅助技术的结合为提高手术控制和精确度提供了巨大的机会。机器人系统和 UBE 的结合可以提高外科医生在微创手术中的精确度,并进一步改善患者的治疗效果。 UBE 还可以透过人工智慧和机器学习的应用来帮助改善手术导引和手术结果。此外,由于这些技术进步,UBE 可能成为复杂手术的首选方法,这可能会推动其在专业医疗设施中的扩张。
与传统手术技术的竞争
儘管UBE的使用越来越多,但传统的开放性手术和其他微创手术仍然经常进行。许多外科医生发现这些试验和测试的手术更加安全,因为数十年的临床资料已经证明了它们的安全性和有效性。此外,医疗保健提供者和医院不愿意投资像 UBE 这样的新技术。由于对传统技术的持续偏好,UBE 市场可能面临重大障碍,这可能会阻碍某些地区或专业的采用。
单侧双端口内视镜市场受到 COVID-19 大流行的严重影响,导致采用和成长放缓。为了优先考虑与 COVID-19 相关的医疗需求并降低院内传播的风险,在大流行早期阶段推迟或取消了包括 UBE 在内的择期手术。此外,由于全球供应链中断以及医疗保健资源重新分配给流行病管理,因此获得 UBE 设备和培训受到阻碍。然而,随着医疗保健系统的调整和择期手术的恢復,UBE 在微创手术中的潜力可能会恢復,特别是在寻求减少术后恢復时间和改善患者预后的市场中引起了人们的关注。
预计可重复使用部分在预测期内将是最大的
预计单侧双边内视镜市场将由可重复使用部分主导。医疗保健提供者广泛采用可重复使用的产品,部分原因是高效的灭菌和消毒程序带来的高回收率,这导致了它们的优越性。根据感染风险对可重复使用的设备进行分类,可以采用客製化的消毒技术,从而提高有效性和安全性。此外,随着微创手术变得越来越普遍,可重复使用的细分市场预计将继续推动市场;然而,对感染控制的日益关注和一次性产品的低维护要求正在推动一次性细分市场的快速成长。
预计门诊手术中心领域在预测期内复合年增长率最高
在单侧双门内视镜市场中,门诊手术中心(ASC)领域预计将以最高的复合年增长率成长。这种扩张的关键驱动因素是专业拥有和营运的 ASC 的增加,以满足对微创外科手术不断增长的需求。 ASC 对患者和医疗保健专业人员有许多有吸引力的好处,包括节省成本和简化当天手术。此外,有利的报销做法和对缩短住院时间的手术的日益渴望也是促使患者转向门诊治疗的因素。
单侧双入口内视镜市场预计将由北美地区主导。非传染性疾病的高盛行率、先进的医疗保健系统以及不断增长的需要微创外科手术的老年人口是促成这一优势的关键因素。有利的报销政策和对尖端外科技术的日益偏好,使美国成为该市场的主要参与者。此外,由于主要市场参与者的存在和持续的技术进步,北美已成为单侧双门户内视镜创新和应用的重要中心,这也对该地区的成长做出了重大贡献。
单侧双功能内视镜市场预计将以亚太地区最高的复合年增长率成长。医疗保健基础设施的快速改善、市场参与企业增加的投资以及促进创新和新技术采用的宽鬆法律规范是推动这一增长的一些因素。由于医疗专业知识的提高和对微创手术的需求不断增长,中国和印度等国家正在引领这一势头。此外,该地区脊椎疾病的发生率不断上升,尤其是老年人,也推动了市场的发展,因为医疗专业人员正在寻求有效和高效的治疗方法。
According to Stratistics MRC, the Global Unilateral Biportal Endoscopy Market is accounted for $977.16 million in 2024 and is expected to reach $1550.62 million by 2030 growing at a CAGR of 8.0% during the forecast period. Spinal surgery is the main application for the sophisticated minimally invasive surgical technique known as unilateral biportal endoscopy (UBE). A high-definition camera and surgical tools are inserted through two tiny incisions on the same side of the body in order to view and treat spinal disorders. Compared to open surgery, UBE has a number of benefits, including less tissue damage, quicker recovery, and less muscle dissection. With the least amount of disturbance to the surrounding structures, the technique enables precise, direct access to the spine, it has grown in popularity for procedures like spinal fusion, discectomy, and decompression because it offers patients a less invasive and more efficient option than traditional techniques.
According to the National Institutes of Health (NIH), minimally invasive spine surgery, including techniques like unilateral biportal endoscopy, has been shown to reduce recovery times by up to 50%, minimize postoperative pain by 30-40%, and decrease hospital stays by 20-30% compared to traditional open spine surgery.
Growing Need for Outpatient Treatments
Outpatient surgeries are becoming more and more popular as a result of healthcare systems around the world focusing more on cutting costs. This model is ideal for UBE since its minimally invasive technique results in shorter hospital stays and faster recovery times, enabling patients to resume their regular activities more quickly. Additionally, an increasing number of insurers are supporting this trend by covering UBE procedures because they understand how efficient and cost-effective they are. It is anticipated that UBE's role in outpatient surgery will grow as healthcare providers seek to reduce operating expenses and the strain on inpatient facilities.
Expensive initial equipment costs
The high expense of the required technology and equipment is one of the main obstacles to the broad use of UBE. The cost of purchasing and maintaining the endoscopic tools, cameras, and sophisticated imaging systems needed for UBE procedures is high. Furthermore, these systems require large investments from hospitals and clinics, which can be prohibitive, particularly in areas with low and middle incomes. Despite the possible long-term cost savings associated with quicker recovery times and shorter hospital stays, these high upfront costs may prevent some healthcare providers from implementing UBE.
Technological developments and robotics integration
The combination of UBE and robotic-assisted technologies offers a significant chance to improve surgical control and precision. Combining robotic systems with UBE could further enhance patient outcomes by giving surgeons more accuracy during minimally invasive procedures. UBE may also be useful in enhancing surgical navigation and results through the application of AI and machine learning. Moreover, UBE may become the method of choice for complex surgeries as a result of these technological advancements, which would propel its expansion in specialty medical facilities.
Competition from conventional surgical techniques
Traditional open surgeries and other minimally invasive procedures are still frequently employed despite the increasing use of UBE. Many surgeons continue to feel more at ease using these tried-and-true techniques because they have been proven safe and effective by decades of clinical data. Furthermore, healthcare providers and hospitals are reluctant to invest in newer technologies like UBE because they frequently prioritize tried-and-true, affordable treatments. The market for UBE may face serious obstacles as a result of this ingrained preference for conventional techniques, which could impede its adoption in particular areas or specialties.
The market for unilateral biportal endoscopy was greatly impacted by the COVID-19 pandemic, which caused a slowdown in adoption and growth. In order to prioritize COVID-19-related healthcare needs and lower the risk of transmission in hospitals, elective surgeries, including those involving UBE, were delayed or cancelled during the early stages of the pandemic. Additionally, the availability of UBE equipment and training was hindered by the disruption of global supply chains and the redirection of healthcare resources towards pandemic management. UBE's potential for minimally invasive surgery, however, attracted renewed attention as healthcare systems adjusted and elective surgeries resumed, especially in markets seeking to shorten recovery times following surgery and enhance patient outcomes.
The Reusable segment is expected to be the largest during the forecast period
The unilateral bilateral endoscopy market is anticipated to be dominated by the reusable segment. Due in large part to their high recoverability rates through efficient sterilization and disinfection procedures, healthcare providers have adopted reusable products widely, which has led to their dominance. The classification of reusable instruments according to the risks of infection enables customized disinfection techniques that improve efficacy and safety. Furthermore, the market is expected to continue to be led by the reusable segment as minimally invasive surgeries gain popularity, but the single-use segment is expected to grow quickly because of growing concerns about infection control and the lower maintenance needs of single-use products.
The Ambulatory Surgery Centers segment is expected to have the highest CAGR during the forecast period
In the unilateral biportal endoscopy market, the ambulatory surgery centers (ASCs) segment is anticipated to grow at the highest CAGR. The rise in professionally owned and operated ASCs, which meet the growing demand for minimally invasive surgical procedures, is the main driver of this expansion. ASCs have a number of benefits that are appealing to patients and healthcare professionals alike, such as cost savings and the ease of same-day surgeries. Moreover, favourable reimbursement practices and a growing desire for procedures that shorten hospital stays are additional factors supporting the move towards outpatient care.
The market for unilateral biportal endoscopy is expected to be dominated by the North American region. The high incidence of non-communicable diseases, the sophisticated healthcare system, and the growing geriatric population that demands minimally invasive surgical procedures are all major contributors to this dominance. Due to its advantageous reimbursement policies and growing preference for cutting-edge surgical techniques, the United States in particular is a major player in this market. Additionally, North America is a key hub for unilateral biportal endoscopy innovations and applications due to the presence of major market players and ongoing technological advancements, which also greatly contribute to the region's growth.
The unilateral biportal endoscopy market is anticipated to grow at the highest CAGR in the Asia-Pacific region. Rapid improvements in healthcare infrastructure, rising market player investments, and a laxer regulatory framework that promotes innovation and the uptake of new technologies are some of the factors driving this growth. Because of their growing medical expertise and rising demand for minimally invasive surgical procedures, nations like China and India are driving this momentum. Furthermore, the market is driven by the increasing incidence of spinal disorders, especially among the elderly population in this area, as medical professionals look for effective and efficient treatment alternatives.
Key players in the market
Some of the key players in Unilateral Biportal Endoscopy market include Stryker Corporation, Karl Storz, Conmed Corporation, Kinetix Lifesciences, Richard Wolf, Jiangsu Bonss Medical Technology Co. Ltd., Smith & Nephew, Maxer Endoscopy GmbH, Endovision Co. Ltd. and Joimax GmbH.
In August 2024, Stryker announced a definitive agreement to acquire care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. The acquisition will strengthen Stryker's growing healthcare IT offering and wirelessly connected medical device portfolio.
In June 2024, Karl Storz Endoscopy-America, a subsidiary of medical technology company Karl Storz Se & Co, has agreed to acquire Asensus Surgical. Under the agreement, KARL STORZ will acquire all outstanding shares of Asensus for $0.35 per share in cash.
In February 2024, Smith+Nephew, the global medical technology company, announces an agreement with NAVBIT to exclusively distribute the NAVBIT SPRINT(TM) in Australia. A single-use, sterile navigation system with everything provided in a small carton, NAVBIT SPRINT(TM) is designed to suit busy surgeons - and its convenient product format makes it extremely practical and cost efficient for hospitals and day surgery environments.